Literature DB >> 8083342

Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis.

A E Koch1, S L Kunkel, L A Harlow, D D Mazarakis, G K Haines, M D Burdick, R M Pope, A Walz, R M Strieter.   

Abstract

We and others have shown that cells obtained from inflamed joints of rheumatoid arthritis (RA) patients produce interleukin-8, a potent chemotactic cytokine for neutrophils (PMNs). However, IL-8 accounted for only 40% of the chemotactic activity for PMNs found in these synovial fluids. Currently, we have examined the production of the novel PMN chemotactic cytokine, epithelial neutrophil activating peptide-78 (ENA-78), using peripheral blood, synovial fluid, and synovial tissue from 70 arthritic patients. RA ENA-78 levels were greater in RA synovial fluid (239 +/- 63 ng/ml) compared with synovial fluid from other forms of arthritis (130 +/- 118 ng/ml) or osteoarthritis (2.6 +/- 1.8 ng/ml) (P < 0.05). RA peripheral blood ENA-78 levels (70 +/- 26 ng/ml) were greater than normal peripheral blood levels (0.12 +/- 0.04 ng/ml) (P < 0.05). Anti-ENA-78 antibodies neutralized 42 +/- 9% (mean +/- SE) of the chemotactic activity for PMNs found in RA synovial fluids. Isolated RA synovial tissue fibroblasts in vitro constitutively produced significant levels of ENA-78, and this production was further augmented when stimulated with tumor necrosis factor-alpha (TNF-alpha). In addition RA and osteoarthritis synovial tissue fibroblasts as well as RA synovial tissue macrophages were found to constitutively produce ENA-78. RA synovial fluid mononuclear cells spontaneously produced ENA-78, which was augmented in the presence of lipopolysaccharide. Immunohistochemical localization of ENA-78 from the synovial tissue of patients with arthritis or normal subjects showed that the predominant cellular source of this chemokine was synovial lining cells, followed by macrophages, endothelial cells, and fibroblasts. Synovial tissue macrophages and fibroblasts were more ENA-78 immunopositive in RA than in normal synovial tissue (P < 0.05). These results, which are the first demonstration of ENA-78 in a human disease state, suggest that ENA-78 may play an important role in the recruitment of PMNs in the milieu of the inflamed joint of RA patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083342      PMCID: PMC295150          DOI: 10.1172/JCI117414

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis.

Authors:  G S Firestein; J M Alvaro-Gracia; R Maki; J M Alvaro-Garcia
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

2.  Functional heterogeneity of human rheumatoid synovial tissue macrophages.

Authors:  A E Koch; P J Polverini; S J Leibovich
Journal:  J Rheumatol       Date:  1988-07       Impact factor: 4.666

3.  Stimulation of neovascularization by human rheumatoid synovial tissue macrophages.

Authors:  A E Koch; P J Polverini; S J Leibovich
Journal:  Arthritis Rheum       Date:  1986-04

4.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.

Authors:  R Altman; E Asch; D Bloch; G Bole; D Borenstein; K Brandt; W Christy; T D Cooke; R Greenwald; M Hochberg
Journal:  Arthritis Rheum       Date:  1986-08

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Elevation of PMN cytosolic free calcium and locomotion stimulated by novel peptides from IL-1-treated human synovial cell cultures.

Authors:  M L Watson; J Westwick; N J Fincham; R D Camp
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

7.  Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms.

Authors:  A E Koch; S L Kunkel; W H Pearce; M R Shah; D Parikh; H L Evanoff; G K Haines; M D Burdick; R M Strieter
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  Neutrophil stimulation: receptor, membrane, and metabolic events.

Authors:  H M Korchak; K Vienne; L E Rutherford; G Weissmann
Journal:  Fed Proc       Date:  1984-09

9.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

10.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.

Authors:  A E Koch; S L Kunkel; L A Harlow; D D Mazarakis; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  58 in total

1.  Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis.

Authors:  Hakan Erdem; Salih Pay; Muhittin Serdar; Ismail Simşek; Ayhan Dinç; Uğur Muşabak; Aysel Pekel; Mustafa Turan
Journal:  Rheumatol Int       Date:  2004-11-03       Impact factor: 2.631

2.  Identification of candidate genes for susceptibility to reactive arthritis.

Authors:  Markus Rihl; Christian Barthel; Andreas Klos; Reinhold E Schmidt; Paul P Tak; Henning Zeidler; Jens G Kuipers
Journal:  Rheumatol Int       Date:  2009-06-09       Impact factor: 2.631

3.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Authors:  Marco Bezzi; Nina Seitzer; Tomoki Ishikawa; Markus Reschke; Ming Chen; Guocan Wang; Caitlin Mitchell; Christopher Ng; Jesse Katon; Andrea Lunardi; Sabina Signoretti; John G Clohessy; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Nat Med       Date:  2018-01-08       Impact factor: 53.440

4.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Authors:  E M Paleolog; R A Fava
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Chemokines in rheumatoid arthritis.

Authors:  Z Szekanecz; R M Strieter; S L Kunkel; A E Koch
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

7.  Molecular Basis of Chemokine CXCL5-Glycosaminoglycan Interactions.

Authors:  Krishna Mohan Sepuru; Balaji Nagarajan; Umesh R Desai; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2016-07-28       Impact factor: 5.157

Review 8.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

Review 9.  The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.

Authors:  Andrew Filer; Karim Raza; Mike Salmon; Christopher D Buckley
Journal:  Front Biosci       Date:  2008-01-01

Review 10.  Role of pro-inflammatory cytokines in rheumatoid arthritis.

Authors:  F M Brennan; R N Maini; M Feldmann
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.